<DOC>
	<DOCNO>NCT01057017</DOCNO>
	<brief_summary>Bevacizumab give 7.5mg/kg . IV 10-90 minute every 3 week disease progression.Panitumumab give 9mg/kg . IV 30-90 minute every 3 week disease progression.Primary Objective : To determine safety every 3 week panitumumab bevacizumab maintenance therapy patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Panitumumab Bevacizumab Maintenance After First-Line FOLFOX-Bevacizumab Patients With Advanced Colorectal Cancer With Wild-Type Ras</brief_title>
	<detailed_description>26 patient advanced colorectal cancer give Bevacizumab 7.5mg/kg . IV 10-90 minute every 3 week disease progression.Panitumumab give 9mg/kg . IV 30-90 minute every 3 week disease progression</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically pathologically confirm advanced colorectal cancer receive FOLFOX/bevacizumab firstline treatment metastatic disease . 2 . Patients must disease progression receive minimum 6 treatment FOLFOX/bevacizumab . Patients stable respond disease FOLFOX/bevacizumab eligible . Bevacizumab need administer cycle FOLFOX . 3 . At least 3 week since prior FOLFOX/bevacizumab . 4 . Wild type ra 5 . No potentially curative treatment option . 6 . ECOG performance status 01 7 . Age &gt; 18 , pregnant breastfeed 8 . Required entry laboratory parameter within 14 day study entry : Granulocytes ≥ 1500/µl ; platelet count ≥ 100,000/µl , Creatinine ≤ 2.0 mg/dl , Bilirubin ≤ 1.5 x upper limit normal , AST ≤ 3 x upper limit normal ( ≤ 5 x upper limit normal patient liver metastasis ) , Magnesium &gt; low limit normal 9 . Life expectancy least 16 week 10 . Must uncontrolled severe , intercurrent illness . 11 . No chemotherapy radiation therapy within last 3 week 12 . No concurrent anticancer therapy . 13 . Signed studyspecific consent form prior study entry 1 . Prior EGFR inhibitor prior irinotecan . 2 . Clinically significant cardiac disease ( e.g. , uncontrolled hypertension [ blood pressure &gt; 150/90 mmHg medication ] , history myocardial infarction within 6 month , ) , New York Heart Association ( NYHA ) Class II great congestive heart failure within 6 month , unstable arrhythmia . Patients atrial arrhythmia must condition well control stable medication . Patients current recent ( within 6 month ) unstable angina also eligible . 3 . Significant bleeding diathesis coagulopathy 4 . Major surgical procedure within 28 day prior start treatment . Portacath placement allow . 5 . Serious , nonhealing wound , ulcer , current healing fracture 6 . History cerebral aneurysms cerebral arteriovenous malformation . 7 . Patients recent ( within 12 month ) arterial thromboembolic event , include transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) , clinically significant peripheral artery disease also exclude . 8 . Brain metastases 9 . Patients history gastrointestinal fistula perforation . 10 . Significant infection coexistent medical condition would preclude protocol therapy . 11 . Interstitial lung disease 12 . Patients organ transplant 13 . Known positive test ( ) HIV infection , hepatitis C virus , acute chronic active hepatitis B infection 14 . Women childbearing potential men sexually active willing/able use medically acceptable form contraception ; exclusion necessary treatment involve study may significantly teratogenic . 15 . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 2 year ( For example , carcinoma situ breast , bladder cervix permissible ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>colorectal cancer</keyword>
</DOC>